TOP AGO TUMOR SECRETS

Hormonal therapy continues to be the cure of first choice for metastatic clients with endocrine-responsive breast cancer (LoE 1a A, In the past ++). The sequential use from the available prescription drugs is determined by the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at enough time of analysis of relapse is usually